Stock NOVO B NOVO NORDISK A/S
Add to a list
To use this feature you must be a member
Log inSign up

Novo Nordisk A/S Share Price

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen
Other stock markets
 09:50:00 06/12/2024 pm IST 		5-day change 1st Jan Change
785.50 DKK +1.88% Intraday chart for Novo Nordisk A/S +3.72% +12.52%
06/12 Novo, Catalent's $16.5 Billion Deal for Weight-Loss Drug Production Gets European Commission Approval DJ
06/12 Catalent's Proposed Acquisition by Novo Holdings Wins European Commission Nod MT

Valuation: Novo Nordisk A/S

Capitalization 3,47500Cr 49TCr 47TCr 43TCr 39TCr 70TCr 41,71900Cr 77TCr 5,37700Cr 1,98800Cr 17,14100Cr 1,85100Cr 1,80900Cr 73,85600Cr P/E ratio 2024 *
34.8x
P/E ratio 2025 * 27.7x
Enterprise value 3,49300Cr 50TCr 47TCr 43TCr 39TCr 70TCr 41,93200Cr 77TCr 5,40400Cr 1,99800Cr 17,22900Cr 1,86000Cr 1,81900Cr 74,23300Cr EV / Sales 2024 *
12.2x
EV / Sales 2025 * 10.1x
Free-Float
70.25%
Yield 2024 *
1.43%
Yield 2025 * 1.86%
More valuation ratios * Estimated data

Chart: Novo Nordisk A/S

Dynamic Chart

Latest news: Novo Nordisk A/S

Novo, Catalent's $16.5 Billion Deal for Weight-Loss Drug Production Gets European Commission Approval 07/12 DJ
Catalent's Proposed Acquisition by Novo Holdings Wins European Commission Nod 07/12 MT
Novo Holdings' $16.5 billion Catalent buy wins EU antitrust approval 06/12 RE
European Equities Traded in the US as American Depositary Tread Water in Friday Trading 06/12 MT
NOVO NORDISK : Interesting equations developing for Novo Nordisk 06/12Alphavalue
Eli Lilly to Expand Facility to Meet Demand for Diabetes, Obesity Treatments -- Update 06/12 DJ
Eli Lilly to Expand Facility to Meet Demand for Diabetes, Obesity Treatments 06/12 DJ
Sector Update: Health Care Stocks Retreat Late Afternoon 06/12 MT
Sector Update: Health Care Stocks Decline Thursday Afternoon 06/12 MT
Novo Nordisk to Cut Prices of Insulin Products by Over 70% 05/12 MT
Novo Nordisk slashes list prices of two insulin products in the US 05/12 FW
Denmark raises 2025 GDP outlook, benefits from Novo Nordisk's growth 05/12 RE
Denmark raises growth forecast again - Novo Nordisk contributing factor 05/12 FW
More news

Last Transcript: Novo Nordisk A/S

Logo Novo Nordisk A/S
Novo Nordisk A/S, Nine Months 2024 Earnings Call, Nov 07, 2024
07/11
More transcripts

Analysts' recommendations: Novo Nordisk A/S

NOVO NORDISK : Interesting equations developing for Novo Nordisk 06/12Alphavalue
Guggenheim Securities lowers target price for Novo Nordisk to DKK 900 (1,012), reiterates Buy - BN 05/12 FW
NOVO NORDISK : Bernstein maintains a Sell rating 04/12 ZD
NOVO NORDISK : JP Morgan reiterates its Buy rating 04/12 ZD
NOVO NORDISK : Gets a Buy rating from JP Morgan 03/12 ZD
More recommendations

Press Releases: Novo Nordisk A/S

Novo Nordisk A/S : The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings Form 6 K 07/12 PU
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings 06/12 GL
Novo Nordisk A/S : Charter of the Chair Committee of the Board of Directors ( charter chair committee 2024 ) 06/12 PU
Novo Nordisk A/S : Charter of the Audit Committee of the Board of Directors ( charter audit committee 2024 ) 06/12 PU
Novo Nordisk A/S : Charter of the People & Governance Committee of the Board of Directors ( charter of people and governance committee 2024 ) 06/12 PU
More press releases

News in other languages: Novo Nordisk A/S

EU gibt grünes Licht für Novo Holding und Catalent 07/12
Dänische Wirtschaft wächst dank Abnehmspritze von Novo Nordisk stärker 05/12
Índices: Un repaso a los selectivos nórdicos 05/12
Novo Nordisk: feu vert au remboursement du Wegovy en France 05/12
Jupiter cherche un nouveau satellite 05/12
More news

Quotes and Performance

1 day+1.88%
1 week+3.72%
Current month+3.72%
1 month+4.80%
3 months-10.89%
6 months-19.30%
Current year+12.52%
More quotes

Course Extremes

1 week
756.00
Extreme 756
789.40
1 month
697.80
Extreme 697.8
789.40
Current year
688.80
Extreme 688.8
1 033.20
1 year
645.00
Extreme 645
1 033.20
3 years
302.20
Extreme 302.2
1 033.20
5 years
165.85
Extreme 165.85
1 033.20
10 years
109.10
Extreme 109.1
1 033.20
More quotes

Managers and Directors: Novo Nordisk A/S

Director TitleAgeSince
Lars Fruergaard Jorgensen CEO
 Chief Executive Officer 58 01/01/2017
Karsten Munk Knudsen DFI
 Director of Finance/CFO 53 15/02/2018
Henrik Ehlers Wulff CTO
 Chief Tech/Sci/R&D Officer 54 01/01/2019
Manager TitleAgeSince
Sylvie Grégoire BRD
 Director/Board Member 62 19/03/2015
Kasim Kutay BRD
 Director/Board Member 59 23/03/2017
Helge Lund CHM
 Chairman 62 22/03/2018
More insiders

ETFs: Novo Nordisk A/S

Name Weight AuM 1st Jan change Investor Rating
XACT NORDEN (UCITS ETF) - SEK ETF XACT NORDEN (UCITS ETF) - SEK
21.31% 203 M€ +14.48%
FIRST TRUST IPOX EUROPE EQUITY OPPORTUNITIES ETF - DISTRIBUTING - USD ETF First Trust IPOX Europe Equity Opportunities ETF - Distributing - USD
10.45% 4 M€ +20.69%
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Yen-Hedged) ETF - JPY
5.40% 20 M€ +16.75% -
More ETFs: Novo Nordisk A/S

Other Pharmaceuticals

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
NOVO NORDISK A/S Stock Novo Nordisk A/S
+1.88%+3.72%+15.77%+121.70%49TCr
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+0.13%+3.94%+40.30%+235.61%74TCr
JOHNSON & JOHNSON Stock Johnson & Johnson
-0.14%-3.68%-4.67%-8.37%36TCr
ABBVIE INC. Stock AbbVie Inc.
+0.01%-3.68%+20.36%+45.19%31TCr
MERCK & CO., INC. Stock Merck & Co., Inc.
-0.44%+1.43%-2.40%+40.41%26TCr
ROCHE HOLDING AG Stock Roche Holding AG
+0.27%+0.59%+2.82%-30.08%24TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
+0.34%+0.40%+5.17%+27.39%21TCr
NOVARTIS AG Stock Novartis AG
-0.63%-3.71%+5.80%+20.34%20TCr
AMGEN INC. Stock Amgen Inc.
-0.64%-3.64%+1.20%+30.55%15TCr
PFIZER, INC. Stock Pfizer, Inc.
+0.12%-1.83%-10.63%-50.02%15TCr
Average +0.21%-0.49%+7.37%+43.27% 31.12TCr
Weighted average by Cap. +0.38%+0.50%+13.94%+82.59%
See all sector performances

Financials

2024 *2025 *
Net sales 29TCr 4.07TCr 3.85TCr 3.57TCr 3.19TCr 5.75TCr 3,44300Cr 6.36TCr 44TCr 16TCr 1,41400Cr 15TCr 15TCr 6,09500Cr 35TCr 4.89TCr 4.63TCr 4.29TCr 3.84TCr 6.92TCr 4,14200Cr 7.66TCr 53TCr 20TCr 1,70200Cr 18TCr 18TCr 7,33300Cr
Net income 10TCr 1.44TCr 1.36TCr 1.26TCr 1.13TCr 2.03TCr 1,21500Cr 2.25TCr 16TCr 5.79TCr 50TCr 5.39TCr 5.27TCr 2,15200Cr 13TCr 1.77TCr 1.68TCr 1.56TCr 1.39TCr 2.51TCr 1,50300Cr 2.78TCr 19TCr 7.16TCr 62TCr 6.67TCr 6.52TCr 2,66100Cr
Net Debt 1.77TCr 251.26Cr 237.77Cr 220.41Cr 197.12Cr 355.24Cr 21TCr 393.25Cr 2.74TCr 1.01TCr 8.74TCr 943.87Cr 922.88Cr 38TCr -47Cr -6.63Cr -6.28Cr -5.82Cr -5.2Cr -9.38Cr -561.74Cr -10Cr -72Cr -27Cr -230.8Cr -25Cr -24Cr -994.45Cr
More financial data * Estimated data

Company Profile

Logo Novo Nordisk A/S
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Employees
71,880
Sector
Pharmaceuticals
Calendar
05/02/2025 - Q4 2024 Earnings Release
More about the company

Quotes

Date Price Change Volume
06/24/06 785.50 kr +1.88% 2,421,773
05/24/05 771.00 kr -1.15% 2,488,660
04/24/04 780.00 kr -0.29% 3,468,775
03/24/03 782.30 kr +0.84% 2,377,343
02/24/02 775.80 kr +2.44% 3,275,021

Delayed Quote Nasdaq Copenhagen, December 06, 2024 at 09:50 pm IST

More quotes

Income Statement and Estimates

income-statement-evolution-chart NOVO-NORDISK-A-S More financial data

Ratings

Trading Rating
Investor Rating
ESG Refinitiv
B
surperformance-ratings-light-chart NOVO-NORDISK-A-SMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
785.50DKK
Average target price
938.17DKK
Spread / Average Target
+19.44%
Consensus
Profit revisions
estimates-change-chart NOVO-NORDISK-A-S Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart NOVO-NORDISK-A-S Company calendar
  1. Stock Market
  2. Equities
  3. NOVO B Stock
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition